Opus Genetics Files Proxy Materials
Ticker: IRD · Form: DEFA14A · Filed: Apr 7, 2025 · CIK: 1228627
Sentiment: neutral
Topics: proxy-filing, regulatory, corporate-governance
TL;DR
Opus Genetics filed proxy docs, no fee. Formerly Ocuphire Pharma.
AI Summary
Opus Genetics, Inc. filed a Definitive Additional Material proxy statement on April 7, 2025. This filing relates to the company's proxy materials and does not involve a fee, as indicated by the filing details. The company was formerly known as Ocuphire Pharma, Inc. and Rexahn Pharmaceuticals, Inc.
Why It Matters
This filing is a routine regulatory submission that provides additional information to shareholders regarding company matters, which is crucial for transparency and shareholder engagement.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement, indicating standard corporate governance procedures rather than a specific event with immediate financial risk.
Key Players & Entities
- Opus Genetics, Inc. (company) — Registrant
- Ocuphire Pharma, Inc. (company) — Former Company Name
- Rexahn Pharmaceuticals, Inc. (company) — Former Company Name
- 20250407 (date) — Filing Date
FAQ
What is the purpose of this DEFA14A filing?
This filing is a Definitive Additional Material proxy statement filed by Opus Genetics, Inc. pursuant to Section 14(a) of the Securities Exchange Act of 1934.
When was this filing submitted?
The filing was submitted on April 7, 2025.
Does this filing involve a payment of a fee?
No, the filing indicates that no fee was paid for this filing.
What were Opus Genetics, Inc.'s previous names?
Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and Rexahn Pharmaceuticals, Inc.
What is the company's primary industry?
Opus Genetics, Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 7, 2025 regarding Opus Genetics, Inc. (IRD).